The Challenge in Bioprocess Development: From Data to Knowledge - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Challenge in Bioprocess Development: From Data to Knowledge
The senior director of Oracle's Life Sciences Business Unit tackles some of the technical issues regarding regulatory standardization, software integration, and the trend toward visualization, among other things.


Pharmaceutical Technology


Gary Montague* is professor of bioprocess control in the School of Chemical Engineering and Advanced Materials, Newcastle University, Newcastle upon Tyne, NE1 7RU, United Kingdom, tel. +44 191 2227265, fax +44 191 2225292. Elaine Martin is professor of industrial statistics in the School of Chemical Engineering and Advanced Materials at Newcastle University.

This article was reprinted with permission from Pharmaceutical Technology Europe, 19 (9), 71–75 (2007).

*To whom all correspondence should be addressed.

References

1. US Food and Drug Administration, Guidance for Industry PAT—A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance, (FDA, Rockville, MD, September 2004), http://www.fda.gov/.

2. A.O. Kirdar et al., "Application of Multivariate Analysis toward Biotech Processes: Case Study of a Cell-Culture Unit Operation," Biotechnol. Prog. 23 (1), 61–67 (2007).

3. A. Inselberg, "Visualization and Data Mining of High-Dimensional Data," Chemomet. Intell. Lab. Syst. 60 (1), 147–159 (2002).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here